Skip to main content
. 2017 Apr 18;7:46482. doi: 10.1038/srep46482

Figure 7. Viral-vectored vaccine (vv) efficacy against a challenge with transgenic P. berghei sporozoites expressing P. vivax CSP VK210 or VK247.

Figure 7

Groups of CD-1 mice (n = 6–10) were immunized with vv expressing PvCSP (N210/247C, N210C, N247C, NC; see Fig. 1) using an Ad prime and MVA-boost regimen. A vv expressing PbCSP was used as control. Two (A–D,F) or 12 (E) weeks after the boost, mice were challenged by intravenous injection of 2,000 transgenic sporozoites expressing PvCSP VK210 or VK247. The Kaplan-Meier curves illustrate the time to 1% parasitaemia (A–F). As a control PbCSP or N210/247C immunized mice were challenged 2 weeks post-boost with wild type P. berghei sporozoites (F). Statistical analysis was performed using the Kaplan-Meier survival curves and P values were calculated using a Kaplan-Meier Log-rank (Mantel-Cox) test. Data was obtained from two individual experiments.